Ken Shroyer is a Board Certified Anatomic Clinical Pathologist with a subspecialty certification in Cytopathology . Ken has been engaged in the development of novel approaches for antibody labeling using nanoparticles for both in vivo imaging and for immunohistochemical applications in collaboration with scientists in biomedical engineering for over six years. More broadly, his work over the past 30 years has been reported in over 140 research manuscripts, many of which are focused on the field of cervical cancer research. In addition to his roles as Chair of the Department of Pathology, staff surgical pathologist and cytopathologist, Dr. Shroyer is the vice Chair of The University Clinical Management Practice Plan, President of the Stony Brook Pathology UFPC, A member of the Executive Board of the Cancer Center, and is Director of the Pathology Core Research Histology Laboratory at Stony Brook Medicine. Ken has a B.A. from Colorado College, a Ph.D. from University of Colorado, and an M.D. from the University of Colorado School of Medicine.
Dr. J Rao is an internationally renowned cytopathologist and established investigator in cancer molecular epidemiology and biomarker studies . Dr. J. Rao is a full professor and the director of Cytopathology, the director of gynecological pathology, and the medical director of cytotechnology school. He has dual appointments in pathology and epidemiology. He is particularly well known for urine cytology, especially in utilizing biomarkers as adjunct for detecting bladder cancer. Dr. Rao has an active role in teaching and research, with continuous funding from NIH or other agencies for cancer biomarker and prevention studies in the last 20 years, with over 100 peer-reviewed research publications.
Dr. Darney is a Professor and Chief of the Department of Obstetrics, Gynecology and Reproductive Sciences, San Francisco General Hospital at the University of California, San Francisco (UCSF), and Founding Director of the University’s Bixby Center for Global Reproductive Health. He is board certified in both obstetrics and gynecology and preventive medicine. With research interests focusing on contraception and reproductive health, Dr. Darney has been a principal investigator for numerous clinical trials and epidemiologic studies, written more than 300 scholarly articles, and edited and contributed to many books. Dr. Darney is an elected member of the Institute of Medicine of the National Academies and has been honored by the American Public Health Association and American College of Obstetricians and Gynecologists for his contributions to family planning research and training. He received his MD degree from UCSF. Dr. Darney also holds a MS degree in demography from the University of London.
Dr. Paul Vichi has over 15 years of research and development experience in oncology focused molecular biology and clinical microbiology, with previous faculty appointments in the departments of Biomedical Technology and Pathology at the University of Vermont, as well as senior positions for commercial R&D. Dr. Vichi joined OncoGenesis in 2008, and is responsible for development of OncoGenesis’ early molecular Screening products. From 2005 to 2008, he was Senior Scientist/Project Manager, Diffraction Ltd. where he led the R&D efforts in nanotech-based solutions for emerging technologies. From 1998 through 2005, Dr. Vichi was an Assistant Professor, Department of Biomedical Technologies, University of Vermont, and prior to that held various post-doctoral positions. Dr. Vichi has a Bachelor of Arts degree in Environmental Science from St. Michael’s College, VT, a PhD in Cell and Molecular Biology from the University of Vermont.
Tom Umbel is an executive leader with more than 30 years of Medical Device and Diagnostics experience. He most recently was the Group SVP of Corporate Development and Marketing for Hologic having worked there for the last 15 years. Tom’s role in managing mergers and acquisitions helped to grow Hologic from a small single-product company to a large diversified Women’s Health company with more than $2.5 Billion in sales. Prior to Hologic, Tom was the President of Direct Radiography Corp. (DRC), later acquired by Hologic. Tom has a BS in Chemical Engineering from Grove City College.
Ron Abelmann has held numerous executive positions in a variety of technology-focused organizations such as Wind River Systems, Vantage Analysis Systems, Varian Instruments, Conrac Corporation and Instron Corporation. In addition, he has extensive and successful experience on the international front, along with participation on numerous boards. Ron holds a BS and MS in Physics from the University of California Los Angeles and a MBA from Stanford University, Palo Alto, California.